SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results
... decreased due to lower royalty income. research and development expenses decreased 34%, or ... of our potential products and complete research and development, including pre-clinical and ... 191,047 146,051 428,739 research and development 793,503 ...Novavax Reports Second Quarter 2009 Financial Results
... the completion of two contracts in 2009. research and development costs were $5.3 million for the ... preclinical studies and clinical trials and other research and development activities; clinical trial ... Operating costs and expenses: research and development 5,297 5,380 9,563 ...Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results
... to $386,612 in the same period in 2008. research and development expenses for the second quarter ... of $48,440 and $99,532, respectively. research and development expenses for the six months ended ... $- Operating costs and expenses: research and development 1,376,253 ...NeurogesX Reports Second Quarter 2009 Results
... to a decline of approximately $1.4 million in research and development costs. During the second quarter ... ---- ---- Operating expenses: research and development(1) $2,780 ... included in operating expenses: (1) research and development $189 $215 $448 ...ALPCO Introduces a Mouse HMW and Total Adiponectin ELISA
... from Dr. Hiroyuki Ebinuma of the Tsukuba research Institute in the journal Clinica Chimica Acta in ... cited in many publications, and is trusted by the research community worldwide for its consistency and ... to grow. Dr. Kelly Scribner Doering, Market research Analyst with ALPCO, states, "Adiponectin is ...GenVec Reports Second Quarter 2009 Financial Results
... program in each period is due mainly to increased research and process development efforts as compared to ... GenVec received a Small Business Innovation and research (SBIR) grant from the National Institute of ... $7,576 $7,592 Operating expenses: research and development 7,096 8,356 14,385 ...InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
... (IPF), which InterMune does not promote. research and development (R&D) expenses in the second ... pre-registration stage. The company also has a research program focused on an early-stage anti-fibrotic ... and a second-generation HCV protease inhibitor research program. For additional information about ...SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
... compared to hardware or platform products. research and development expenses were $10.2 million for ... million for the same period in the prior year. research and development expenses for the second quarter ... Ms. Keller brings more than 25 years of clinical research experience across a broad range of therapeutic ...OncoGenex Reports Second Quarter 2009 Financial Results
... to $7.0 million from $5.4 million in 2008. research and development expenses for the second quarter ... in 2008. For the six months ended June 30, 2009 research and development expenses increased to $5.3 ... in the first six months of 2008 was a Scientific research and Development (SRED) claim, which offset R D ...Transposagen Creates a Rat Model of the Human Immune System
... technologies. Knockout rats are pharmaceutical research models with single gene disruptions that mimic ... research. The production of animal models for research is a $1.2 billion/year market and the genetically ... care and community engagement. A major national research center and academic medical center, its faculty ...The Breast Cancer Therapeutics Market in Australia
... explains Carole Gaffud, Frost & Sullivan research Analyst. "There are several new targeted ... care. Frost & Sullivan's latest research service on The Breast Cancer Therapeutics Market ... CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, ...UCLA welcomes startup to new incubator space at California NanoSystems Institute
... was established in March to nurture early-stage research and accelerate the commercial translation of ... with access to CNSI core lab facilities for research and development. "We consider ourselves very ... startup companies and early-stage technology research projects that originate at UCLA. The incubator ...Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
... original agreement, a $1.8 million decrease in research and development expenses related to KRX-0401, and a $1.0 million decrease in research and development expenses related to the cessation ... attributable to a $26.9 million decrease in research and development expenses related to the cessation ...Amicus Therapeutics Announces Second Quarter 2009 Financial Results
... Programs Amicus continues to invest in research to assess the potential for applying its ... in Parkinson's disease and is investing in new research aimed at evaluating disease targets for other ... (1985 - 1987), and President and CEO of Bethesda research Labs (1982 - 1983). He currently serves on the ...GeoVax Labs, Inc. Provides Clinical Studies Update
... University of Rochester; Fred Hutchinson Cancer research Center, Seattle; the San Francisco Department of ... developer of the vaccine and Senior V.P. of research and Development. "The therapeutic trials should ... developed by Dr. Harriet Robinson, Senior V.P. of research and Development, through a collaboration of ...Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
... depressed gross margin for that product. research and development ("R&D") ... 96.4 142.9 180.0 233.2 research and development(2) 158.7 136.4 ... and $19.1 million have been reclassified from research and development to Selling, general ...Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
... increase in net loss was primarily due to higher research and development expenses. research and development expenses in the second quarter of ... progress and likelihood of success of its product research and development programs, the timing and status ...SK Life Sciences has Licensed Pristima
... Inc. (SKLSI), has licensed Pristima for its research and Development facility in Fair Lawn, New ... Inc. (SKLSI), has licensed Pristima for its research and Development facility in Fair Lawn, New Jersey. After extensive research and evaluation of the products on the market, ...Plastics that convert light to electricity could have a big impact
... electricity and can be easily manufactured. A research team headed by David Ginger, a University of ... materials considered basic to organic solar cell research because their response to forces such as heating ... are Liam Pingree and Obadiah Reid of the UW. The research was funded by the National Science Foundation and ...SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS
... specified conditions. Senomyx will also receive research fees, payments upon the achievement of specified ... revenue in 2009 compared to 2008. research and development expenses, including non-cash ... the second quarter of 2008, a decrease of 3%. research and development expenses, including non-cash ...Techne Corporation Releases Unaudited Fourth Quarter Results for Fiscal Year 2009
... ======== ======== research and development expenses increased $187,000 ... products, the levels and particular directions of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general ...W.M. Keck Foundation Awards $1 Million to Hutchinson Center Scholar to Study How Cells Go Awry
... how cancer cells cheat - Fred Hutchinson Cancer research Center basic scientist Wenying Shou, Ph.D., has ... and Bruce Clurman, M.D., Ph.D., of the Clinical research and Human Biology divisions (1999). The ... the Keck Distinguished Young Scholars in Medical research program was designed to support ...International Milk Genomics & Human Health Symposium Speaker Program Announced
... under the organization of the California Dairy research Foundation (CDRF), the symposium will gather ... milk and Michael Affolter of the Nestlé research Center addressing qualitative and quantitative ... data exchange, coordination of pre-competitive research to develop baseline data, and providing a ...NovaBay(R) Pharmaceuticals Names Roy J. Wu as Senior Vice President for Business Development
... Wu completed numerous licensing agreements and research collaborations with companies including Novartis, ... development for Quintiles-BRI, a clinical research organization, after working for 16 years at ... beginning as a chemist at the Syntex research Institute of Pharmaceutical Sciences and ...Model predicts evolution of Mediterranean landscape following fires
... An international research team has developed a mathematical and ... of forest fires. In order to carry out this research study, published recently in the journal ... affecting Mediterranean areas. In fact, this research study is part of a broader study into changes in ...Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
... by the year-to-date cash utilization. research and development expenses were $4.6 million for ... ---- ---- Operating expenses research and development $4,648 $5,501 ... ended June 30, 2009 and 2008, respectively. research and development expense and general and ...Senesco Technologies Enters Into Agreements For Additional $700,000 In Financing
... which is the venture capital affiliate of Cato research Ltd., a global contract research and development organization currently assisting ... to further advance its multiple myeloma research and development program with the goal of ...